Three trials of short-acting GLP-1 receptor agonists showed slowed motor decline in Parkinson's disease, though the dedicated EVOKE trial of semaglutide for early Alzheimer's disease did not demonstrate significant benefit
Intellectual property protections pursued by pharmaceutical manufacturers
The Expanding Demand That Makes All of This More Urgent The manufacturing challenge being described here is not a temporary response to the obesity and diabetes market
Eine kohlenhydratreiche Mahlzeit oder ein kohlenhydrathaltiger Drink zusammen mit L-Carnitin erhht die Aufnahmerate in den Muskel signifikant
Kecel-Gunduza, S., Kocb, E., Bicaka, B., Kokcub, Y., Ozela, A
The value of fasting in the GLP-1 context is not primarily about adding more weight loss